Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
15 12 2022
Historique:
accepted: 14 06 2022
received: 31 01 2022
pubmed: 8 7 2022
medline: 20 12 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

According to expert guidelines, lymph node surgical excision is the standard of care for lymphoma diagnosis. However, core needle biopsy (CNB) has become widely accepted as part of the lymphoma diagnostic workup over the past decades. The aim of this study was to present the largest multicenter inventory of lymph nodes sampled either by CNB or surgical excision in patients with suspected lymphoma and to compare their diagnostic performance in routine pathologic practice. We reviewed 32 285 cases registered in the French Lymphopath network, which provides a systematic expert review of all lymphoma diagnoses in France, and evaluated the percentage of CNB and surgical excision cases accurately diagnosed according to the World Health Organization classification. Although CNB provided a definitive diagnosis in 92.3% and seemed to be a reliable method of investigation for most patients with suspected lymphoma, it remained less conclusive than surgical excision, which provided a definitive diagnosis in 98.1%. Discordance rates between referral and expert diagnoses were higher on CNB (23.1%) than on surgical excision (21.2%; P = .004), and referral pathologists provided more cases with unclassified lymphoma or equivocal lesion through CNB. In such cases, expert review improved the diagnostic workup by classifying ∼90% of cases, with higher efficacy on surgical excision (93.3%) than CNB (81.4%; P < 10-6). Moreover, diagnostic concordance for reactive lesions was higher on surgical excision than CNB (P = .009). Overall, although CNB accurately diagnoses lymphoma in most instances, it increases the risk of erroneous or nondefinitive conclusions. This large-scale survey also emphasizes the need for systematic expert review in cases of lymphoma suspicion, especially in those sampled by using CNB.

Identifiants

pubmed: 35797472
pii: S0006-4971(22)00885-0
doi: 10.1182/blood.2022015520
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2573-2583

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology.

Auteurs

Charlotte Syrykh (C)

Département de Pathologie, Institut Universitaire du Cancer, Centre Hospitalo-Universitaire (CHU) de Toulouse, Toulouse, France.

Charlotte Chaouat (C)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Besançon, Besançon, France.

Elsa Poullot (E)

Département de Pathologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France.
INSERM U955, Université Paris-Est, Créteil, France.

Nadia Amara (N)

Département de Pathologie, Institut Universitaire du Cancer, Centre Hospitalo-Universitaire (CHU) de Toulouse, Toulouse, France.

Virginie Fataccioli (V)

Département de Pathologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France.
INSERM U955, Université Paris-Est, Créteil, France.

Marie Parrens (M)

Département de Pathologie, Hôpital du Haut Lévêque, Bordeaux, France.
INSERM U1053, Université de Bordeaux2, Bordeaux, France.

Alexandra Traverse-Glehen (A)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) Lyon-Sud, Lyon, France.

Thierry-Jo Molina (TJ)

Département de pathologie, Université de Paris, Assistance Publique - Hôpitaux de Paris (AP-HP), Necker-Enfants Malades et Robert Debre, Paris, France.

Luc Xerri (L)

Département de pathologie, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique (CNRS) UMR7258, Université d'Aix-Marseille, UM105, Marseille, France.

Laurent Martin (L)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Dijon, Dijon, France.

Romain Dubois (R)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Lille, Lille, France.

Vanessa Lacheretz-Szablewski (V)

Département de Pathologie et d'Oncobiologie, Centre Hospitalo-Universitaire (CHU) Montpellier, Montpellier, France.

Marie-Christine Copin (MC)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Lille, Lille, France.
Département de Pathologie, Université d'Angers, Université de Nantes, Centre Hospitalo-Universitaire (CHU) Angers, Inserm, Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCI2NA), Structure Fédérative de Recherche (SFR) Interactions Cellulaires et Applications Thérapeutiques (ICAT), Angers, France.

Anne Moreau (A)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Nantes, Nantes, France.
Département de Pathologie, Centre Hospitalier Départemental (CHD) Vendée, La Roche sur Yon, France.

Marie-Pierre Chenard (MP)

Département de Pathologie, Centre Hospitalo-Universitaire (CHU) de Strasbourg, France.

Bastien Cabarrou (B)

Département de Biostatistiques, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse, France.

Amélie Lusque (A)

Département de Biostatistiques, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse, France.

Philippe Gaulard (P)

Département de Pathologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France.
INSERM U955, Université Paris-Est, Créteil, France.

Pierre Brousset (P)

Département de Pathologie, Institut Universitaire du Cancer, Centre Hospitalo-Universitaire (CHU) de Toulouse, Toulouse, France.
INSERM, U1037, Centre de Recherche en Cancérologie de Toulouse-Purpan, laboratoire d'excellence TOUCAN, Toulouse, France.

Camille Laurent (C)

Département de Pathologie, Institut Universitaire du Cancer, Centre Hospitalo-Universitaire (CHU) de Toulouse, Toulouse, France.
INSERM, U1037, Centre de Recherche en Cancérologie de Toulouse-Purpan, laboratoire d'excellence TOUCAN, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH